camptothecin has been researched along with Cancer of Cervix in 89 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (16.85) | 18.2507 |
| 2000's | 37 (41.57) | 29.6817 |
| 2010's | 35 (39.33) | 24.3611 |
| 2020's | 2 (2.25) | 2.80 |
| Authors | Studies |
|---|---|
| Jeong, YT; Kim, SK; Pallela, R; Park, DH; Parthiban, P | 1 |
| Escobar-Sánchez, ML; Flores, SM; Hernández-Rodríguez, M; Laskar, S; López-Muñoz, H; López-Ortiz, M; Regla, I; Sánchez-Sánchez, L | 1 |
| Liu, D; Liu, F; Liu, L; Wei, P; Yi, T; Yuan, W; Zhang, M | 1 |
| Altwerger, G; Azodi, M; Bellone, S; Bianchi, A; Bonazzoli, E; Buza, N; Han, C; Huang, GS; Hui, P; Lopez, S; Manara, P; Manzano, A; Menderes, G; Perrone, E; Ratner, E; Santin, A; Schwartz, PE; Silasi, DA; Tymon-Rosario, J; Zammataro, L; Zeybek, B | 1 |
| Guo, Z; He, L; Hu, Z; Janardhan, A; Kathera, C; Kumar, AK; Luo, L; Ma, Z; Mao, H; Pan, F; Wu, T; Yang, H; Yang, Y; Zhou, S; Zhu, H | 1 |
| Chuma, M; Fujino, H; Fukushima, K; Hamano, H; Horinouchi, Y; Ikeda, Y; Imanishi, M; Ishizawa, K; Izawa-Ishizawa, Y; Kirino, Y; Mitsui, M; Nakamura, T; Nimura, T; Okada, N; Takechi, K; Tamaki, T; Teraoka, K; Yanagawa, H; Zamami, Y | 1 |
| Bhuniya, S; Mishra, N; Nedungadi, D; Podder, A; Rashmi, R | 1 |
| Hwang, JY; Kong, IK; Yuan, YG; Zhang, S | 1 |
| Baik, M; Choi, YJ; Ho, JY; Hur, SY; Ko, M; Lee, H; Lee, S; Lee, SU; Liu, JJ; Park, JY | 1 |
| Akashi, Y; Matsuura, M; Saito, T; Satohisa, S; Suzuki, M; Suzuki, T; Tanaka, R; Teramoto, M | 1 |
| Miura, Y; Shoji, T; Sugiyama, T; Takatori, E; Takeuchi, S; Yoshizaki, A | 1 |
| Abou Taleb, H; Baba, T; Hamanishi, J; Kido, A; Konishi, I; Matsumura, N; Togashi, K; Yamaguchi, K; Yamanoi, K; Yoshioka, Y | 1 |
| Kagabu, M; Kumagai, S; Miura, F; Omi, H; Sato, A; Shoji, T; Sugiyama, T; Takatori, E; Takeuchi, S; Yoshizaki, A | 1 |
| Cassinelli, G; De Cesare, M; Lanzi, C; Zaffaroni, N; Zuco, V | 1 |
| Chen, D; Gao, K; Li, L; Liu, C; Wang, H; Yang, Z; Yao, D; Yu, J; Zhang, J | 1 |
| Chen, G; Cheng, Y; Hong, L; Hu, M; Huang, J; Li, B; Zhou, L | 1 |
| Chen, Y; Feng, Y; Fu, S; Qin, X; Sun, X; Wu, J; Yang, B; You, H; Yu, Y; Zhang, G | 1 |
| Abiko, K; Abou-Taleb, HA; Baba, T; Hamanishi, J; Horikawa, N; Kitamura, S; Konishi, I; Koshiyama, M; Matsumura, N; Murakami, R; Taha, AA; Yamaguchi, K; Yamanoi, K | 1 |
| Han, J; Kim, JH; Kim, JS; Kumar, R; Shin, WS; Verwilst, P | 1 |
| Chen, Ch; Cheng, YX; Hu, M; Huang, JL; Li, BL; Li, MQ; Pan, F; Zhang, QF | 1 |
| Kimura, T; Kobayashi, E; Kozasa, K; Mabuchi, S; Owa, T; Tomimatsu, T; Tsutui, T; Yamashita, M; Yoki, T; Yokoi, E | 1 |
| Fan, Z; Hou, Z; Jiang, Y; Li, Y; Lu, Y; Wu, S; Yang, X | 1 |
| Chen, G; Han, X; Liang, F; Liu, Y; Ma, D; Ma, X; Meng, L; Qin, X; Song, X; Wang, S; Weng, D; Weng, Y; Xia, X; Xing, H; Xu, G; Zhou, J | 1 |
| Hasegawa, K; Kokawa, K; Konishi, I; Nishida, M; Nishimura, R; Noguchi, H; Saji, F; Takizawa, K; Umesaki, N; Yamamoto, K | 1 |
| Fujiwara, K; Furuya, K; Goto, T; Hirata, J; Horie, K; Ishii, K; Kato, M; Kikuchi, Y; Kino, N; Kita, T; Sasaki, N; Takahashi, M; Takano, M; Yokota, H; Yoshikawa, T | 1 |
| Baker, JR; Desai, A; Huang, B; Tang, S; Thomas, TP | 1 |
| Dalenc, F; Delannes, M; El Demery, M; Fabbro, M; Gladieff, L; Guichard, F; Kerr, C; Kurtz, JE; Paraiso, D; Pujade-Lauraine, E | 1 |
| Hatayama, S; Honda, T; Kagabu, M; Kaido, Y; Kumagai, S; Miura, F; Morohara, Y; Murai, M; Omi, H; Satoh, A; Shoji, T; Sugiyama, T; Takatori, E; Yoshizaki, A | 1 |
| Akiyama, F; Kawamata, Y; Matsumura, M; Omatsu, K; Ota, T; Sakamoto, K; Takeshima, N; Takizawa, K; Tanaka, H; Umayahara, K | 1 |
| Apolloni, C; Ditto, A; Frigerio, L; Melpignano, M; Panici, PB; Pignata, S; Raspagliesi, F; Scambia, G; Scollo, P; Selvaggi, L | 1 |
| Hwang, JH; Kang, S; Lim, MC; Park, SY; Seo, SS | 1 |
| Li, Y; Liu, J; Ren, Y | 1 |
| Cao, LP; Liang, LZ; Liu, JH; Min, Z; Xiong, Y | 1 |
| Bai, T; Kobayashi, A; Matsuoka, T; Sasaki, N; Tanaka, J; Tanaka, T; Tanizaki, Y; Toujima, S; Utsunomiya, H; Utsunomiya, T; Yamamoto, M; Yukawa, K | 1 |
| Huang, H; Li, H; Liu, JH | 1 |
| Hiura, M; Kiguchi, K; Kita, T; Kokawa, K; Kubushiro, K; Mizutani, K; Nishimura, R; Sugiyama, T; Takizawa, K; Yaegashi, N; Yamaguchi, S; Yamamoto, K | 1 |
| Hirota, S; Inoue, K; Ito, Y; Kanazawa, R; Komori, S; Maeda, H; Tsubamoto, H | 1 |
| Aoki, D; Banno, K; Kisu, I; Kobayashi, Y; Masuda, K; Nomura, H; Susumu, N; Tominaga, E; Tsuji, K; Ueki, A; Yamagami, W; Yanokura, M | 1 |
| Akimoto, Y; Hamasaki, A; Honda, H; Kaneko, M; Okamoto, K; Oshita, T; Takao, Y; Tanimoto, H; Teramoto, H; Teramoto, M | 1 |
| Kiguchi, K; Kobayashi, Y; Kondo, H; Ohara, T; Suzuki, N; Tozawa, A; Yahagi, N; Yoshida, A; Yoshioka, N | 1 |
| Verschraegen, CF | 1 |
| Charuchinda, C; Chitapanarux, I; Lorvidhaya, V; Pukanhapan, N; Sukthomya, V; Tonusin, A | 1 |
| Chanslip, Y; Pattaranutaporn, P; Suntornpong, N; Thephamongkhol, K | 1 |
| Fujiwara, H; Kikuchi, Y; Kita, T; Komiyama, S; Konno, R; Machida, S; Mikami, M; Ohwada, M; Suzuki, M; Takano, M | 1 |
| Benedicic, Ch; Petru, E; Pickel, H; Seewann, A | 1 |
| Inciūra, A; Juozaityte, E | 1 |
| Cerman, J; Cervinka, M; Radocha, J; Rudolf, E | 1 |
| Hashiguchi, Y; Kawamura, N; Miyama, M; Nakata, S; Negoro, S; Nishimura, S; Tsuda, H | 1 |
| Blessing, JA; McGehee, R; Monk, BJ; Muggia, FM | 1 |
| Ermakova, NA; Mikhaĭlichenko, TD; Moiseenko, VM; Orlova, RV; Protsenko, SA; Teletaeva, GM; Urmancheeva, AF | 1 |
| Fujii, T; Fushiki, H; Hasegawa, K; Izumi, R; Nishida, M; Nishimura, R; Takizawa, K; Tanaka, T; Umesaki, N; Yamamoto, K | 1 |
| Terauchi, F | 1 |
| Kinoshita, K; Tanaka, M; Yoshida, M | 1 |
| Tanaka, T; Umesaki, N; Yukawa, K | 1 |
| Chen, SY; Chen, TH; Gu, MJ; Ma, D; Song, XJ; Wang, CY; Zhang, QH; Zhu, T | 1 |
| Kokawa, K; Tanaka, T; Umesaki, N | 1 |
| Bai, T; Tanaka, T; Umesaki, N; Yukawa, K | 1 |
| Ishihara, A; Kihira, T; Nomura, Y; Tanaka, H | 1 |
| Allaire, N; Amatucci, J; Bailly, V; Bottiglio, C; Browning, JL; Carmillo, A; Crowell, T; Ding, J; Fawell, S; Garber, E; Griffith, L; Heaney, G; Hoffman, R; Jarpe, M; Kelly, R; LePage, D; Lukashev, M; Lukashin, A; Mackay, F; Meier, W; Miatkowski, K; Ngam-ek, A; Perrin, S; Prentice, H; Reff, M; Silverio, E; Szeliga, K; Violette, SM; Wilson, C; Wortham, K; Xu, X; Yang, D; Yang, W; Zeng, W | 1 |
| Jobo, T | 1 |
| Shi, W; Yu, S | 1 |
| Anzai, N; Hiruma, R; Kamide, T; Kamiya, N; Kotake, Y; Matsumoto, R; Sasaki, H; Shinozaki, H; Tada, A; Wachi, T | 1 |
| Tanaka, T; Umesaki, N; Utsunomiya, H; Utsunomiya, T | 1 |
| Furue, H | 1 |
| Terada, K | 1 |
| Eisenhauer, EA; Vermorken, JB | 1 |
| Edwards, CL; Ende, K; Fishman, A; Freedman, RS; Hord, M; Kaplan, AL; Kavanagh, JJ; Kieback, D; Kudelka, AP; Levy, T; Llerena, E; Steger, M; Verschraegen, CF | 1 |
| Armand, JP; Couteau, C; Terret, C | 1 |
| Fujimura, M; Fushiki, H; Hidaka, T; Hori, S; Izumi, R; Yamakawa, Y | 1 |
| Bailey, H; Durivage, HJ; Gelder, M; Irvin, WP; Potkul, RK; Price, FV; Rosenbluth, R | 1 |
| Chang, L; Ogita, S; Tanaka, T; Umesaki, N | 1 |
| Kavanagh, JJ; Kudelka, AP; Verschraegen, CF | 1 |
| Blessing, JA; Chafe, W; Kohler, M; Levenback, C; Look, KY; Roman, LD | 1 |
| Andoh, T; Sugimoto, Y; Tsuruo, T; Yanase, K | 1 |
| Fujiyoshi, K; Hiura, M; Kumagai, S; Nishida, T; Nishio, S; Okura, N; Sugiyama, T; Umesaki, N; Yakushiji, M | 1 |
| Chauvergne, J; Chevallier, B; Dieras, V; Fargeot, P; Fumoleau, P; Krakowski, Y; Lentz, MA; Lhommé, C; Matthieu-Boué, A; Mignard, D; Misset, JL; Rebattu, P; Roche, H; Van Glabbeke, M; Vennin, P | 1 |
| Sandler, A; van Oosterom, AT | 1 |
| Hatae, M; Hiura, M; Ikeda, M; Kudoh, R; Noda, K; Ohashi, Y; Saji, F; Sato, S; Sugiyama, T; Takahashi, T; Takeuchi, S; Terashima, Y; Tomoda, Y; Umesaki, N; Yajima, A; Yakushiji, M | 1 |
| Kamura, T; Sugiyama, T; Ushijima, K | 1 |
| Fujiyoshi, K; Hasuo, Y; Hirai, N; Kamura, T; Kumagai, S; Nishida, T; Nishio, S; Oota, S; Sugiyama, T; Tomioka, Y | 1 |
| Chen, BM; Chen, JY; Kao, M; Lin, JB; Roffler, SR; Yu, MH | 1 |
| Saltz, LB | 1 |
| Hasuo, Y; Kamura, T; Nishida, T; Sugiyama, T | 1 |
| Fujiyoshi, K; Kamura, T; Kumagai, S; Nishida, T; Ota, S; Sugiyama, T; Yoshimura, O | 1 |
| Donato, NJ; Ling, YH; Perez-Soler, R | 1 |
| Choy, H; MacRae, R | 1 |
| Carson, LF; Leung, BS; Padilla, LA | 1 |
| de Bruijn, P; Loos, WJ; Mathijssen, RH; Nooter, K; Sparreboom, A; Verweij, J | 1 |
| Akiya, K; Dobashi, K; Fujimoto, S; Hasumi, K; Negishi, Y; Suzuki, M; Takeuchi, S; Tamaya, T; Tanaka, K; Terashima, Y | 1 |
12 review(s) available for camptothecin and Cancer of Cervix
| Article | Year |
|---|---|
Irinotecan for the treatment of cervical cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Female; Gastrointestinal Diseases; Humans; Irinotecan; Topoisomerase I Inhibitors; Uterine Cervical Neoplasms | 2002 |
Palliative cytostatic treatment of cervical carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Irinotecan; Mitomycin; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Survival Analysis; Uterine Cervical Neoplasms; Vindesine | 2003 |
[The guidelines for diagnostics and treatment of cervical cancer].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hysterectomy; Ifosfamide; Irinotecan; Lymph Node Excision; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Palliative Care; Practice Guidelines as Topic; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Time Factors; Uterine Cervical Neoplasms | 2004 |
[Irinotecan hydrochloride (CPT-11) for advanced cervical cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Irinotecan; Mitomycin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Topoisomerase I Inhibitors; Treatment Outcome; Uterine Cervical Neoplasms | 2004 |
[Irinotecan hydrochloride (CPT-11)].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Humans; Irinotecan; Leukemia L1210; Lung Neoplasms; Ovarian Neoplasms; Uterine Cervical Neoplasms | 1994 |
[Development of new anti-cancer agents in Europe].
Topics: Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Europe; Female; France; Humans; Irinotecan; Japan; Lung Neoplasms; Ovarian Neoplasms; Uterine Cervical Neoplasms | 1996 |
New drugs in gynecologic oncology.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Endometrial Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Humans; Ovarian Neoplasms; Platinum Compounds; Uterine Cervical Neoplasms | 1996 |
CPT-11: the European clinical development.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Female; Humans; Irinotecan; Lung Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms | 1996 |
Irinotecan in cervical cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Irinotecan; Topoisomerase I Inhibitors; Uterine Cervical Neoplasms | 1998 |
Irinotecan in cancers of the lung and cervix.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Female; Humans; Irinotecan; Lung Neoplasms; Uterine Cervical Neoplasms | 1999 |
[New regimens for the treatment of gynecologic cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Taxoids; Thrombocytopenia; Uterine Cervical Neoplasms | 2000 |
Irinotecan and radiation in combined-modality therapy for solid tumors.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Radiotherapy, Adjuvant; Topoisomerase I Inhibitors; Uterine Cervical Neoplasms | 2001 |
22 trial(s) available for camptothecin and Cancer of Cervix
| Article | Year |
|---|---|
The efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer: A randomized multicenter study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Hysterectomy; Irinotecan; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Uterine Cervical Neoplasms; Young Adult | 2016 |
Phase I Clinical Study of Irinotecan Plus S-1 in Patients With Advanced or Recurrent Cervical Cancer Previously Treated With Platinum-Based Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Drug Combinations; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur; Uterine Cervical Neoplasms | 2016 |
Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Uterine Cervical Neoplasms | 2009 |
Phase I study of irinotecan and cisplatin in combination with pelvic radiotherapy in the treatment of locally advanced cervical cancer: A GINECO trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Camptothecin; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Radiotherapy; Uterine Cervical Neoplasms | 2010 |
A phase 2 multicenter study of irinotecan and cisplatinum as neoadjuvant treatment in patients with locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Female; Humans; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms | 2010 |
Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix.
Topics: Adult; Aged; Antineoplastic Agents; Blood Cells; Camptothecin; Digestive System; Disease Progression; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Incidence; Middle Aged; Neoplasm Recurrence, Local; Nervous System; Respiratory System; Skin; Topoisomerase I Inhibitors; Treatment Failure; Uterine Cervical Neoplasms | 2011 |
Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Humans; Hysterectomy; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Uterine Cervical Neoplasms; Young Adult | 2012 |
Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2003 |
Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Treatment Outcome; Uterine Cervical Neoplasms | 2003 |
Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Recombinant Proteins; Recurrence; Uterine Cervical Neoplasms | 2004 |
Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Uterine Cervical Neoplasms | 2004 |
Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Female; Humans; Irinotecan; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Prospective Studies; Uterine Cervical Neoplasms | 2004 |
Preoperative chemotherapy with irinotecan and mitomycin for FIGO stage IIIb cervical squamous cell carcinoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Hysterectomy; Irinotecan; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm Staging; Pilot Projects; Uterine Cervical Neoplasms | 2005 |
Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in elderly Japanese patients with gynecological malignancies: a pilot study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Irinotecan; Japan; Mitomycin; Ovarian Neoplasms; Pilot Projects; Salvage Therapy; Uterine Cervical Neoplasms | 2006 |
Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Female; Humans; Incidence; Irinotecan; Middle Aged; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms | 1997 |
A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Patient Satisfaction; Pilot Projects; Platinum Compounds; Remission Induction; Safety; Uterine Cervical Neoplasms; Vomiting | 1998 |
A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Disease Progression; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Treatment Outcome; Uterine Cervical Neoplasms | 1998 |
Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Uterine Cervical Neoplasms | 1999 |
Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Diarrhea; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms | 1999 |
Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Prospective Studies; Topoisomerase I Inhibitors; Treatment Outcome; Uterine Cervical Neoplasms | 2000 |
[Neoadjuvant chemotherapy with cisplatin and CPT-11 for advanced cervical cancer].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Uterine Cervical Neoplasms | 2000 |
[A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Irinotecan; Leukopenia; Middle Aged; Ovarian Neoplasms; Uterine Cervical Neoplasms | 1991 |
55 other study(ies) available for camptothecin and Cancer of Cervix
| Article | Year |
|---|---|
Synthesis of polyfunctionalized piperidone oxime ethers and their cytotoxicity on HeLa cells.
Topics: Antineoplastic Agents; Cell Survival; Ethers; Female; HeLa Cells; Humans; Oximes; Piperidones; Structure-Activity Relationship; Uterine Cervical Neoplasms | 2011 |
Identification of (1S,4S)-2,5-diazabicyclo[2.2.1]heptane-dithiocarbamate-nitrostyrene hybrid as potent antiproliferative and apoptotic inducing agent against cervical cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; HeLa Cells; Humans; Molecular Structure; Nitro Compounds; Structure-Activity Relationship; Styrene; Thiocarbamates; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2018 |
A Smart Theranostic Prodrug System Activated by Reactive Oxygen Species for Regional Chemotherapy of Metastatic Cancer.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Liberation; Female; Humans; Nanoparticles; Prodrugs; Reactive Oxygen Species; Theranostic Nanomedicine; Uterine Cervical Neoplasms | 2022 |
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cell Adhesion Molecules; Cell Line, Tumor; Cell Survival; Female; Humans; Immunoconjugates; Uterine Cervical Neoplasms | 2020 |
Synergistic antitumor effect of combined paclitaxel with FEN1 inhibitor in cervical cancer cells.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carboplatin; Cell Line, Tumor; Doxorubicin; Drug Synergism; Female; Flap Endonucleases; Humans; Mice; Mice, Inbred BALB C; Paclitaxel; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Irinotecan-induced neutropenia is reduced by oral alkalization drugs: analysis using retrospective chart reviews and the spontaneous reporting database.
Topics: Adult; Aged; Antacids; Antineoplastic Agents, Phytogenic; Buffers; Camptothecin; Cholagogues and Choleretics; Diarrhea; Female; Humans; Intestines; Irinotecan; Magnesium Oxide; Male; Middle Aged; Neutropenia; Retrospective Studies; Sodium Bicarbonate; Topoisomerase I Inhibitors; Ursodeoxycholic Acid; Uterine Cervical Neoplasms; Uterine Neoplasms | 2019 |
Monitoring of topoisomerase (I) inhibitor camptothecin release from endogenous redox-stimulated GO-polymer hybrid carrier.
Topics: Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Carriers; Drug Delivery Systems; Drug Monitoring; Female; Glutathione; Humans; Microscopy, Atomic Force; Microscopy, Electron, Transmission; Oxidation-Reduction; Polymers; Topoisomerase I Inhibitors; Uterine Cervical Neoplasms | 2018 |
Silver Nanoparticles Potentiates Cytotoxicity and Apoptotic Potential of Camptothecin in Human Cervical Cancer Cells.
Topics: Apoptosis; Camptothecin; Female; Humans; Metal Nanoparticles; Silver; Uterine Cervical Neoplasms | 2018 |
CKD-602, a topoisomerase I inhibitor, induces apoptosis and cell-cycle arrest and inhibits invasion in cervical cancer.
Topics: Animals; Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Female; Flow Cytometry; G2 Phase Cell Cycle Checkpoints; HeLa Cells; Humans; Mice, Inbred BALB C; Mice, Nude; Topoisomerase I Inhibitors; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Low-dose SN-38 with paclitaxel induces lethality in human uterine cervical adenocarcinoma cells by increasing caspase activity.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspase 3; Caspase 7; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Synergism; Female; Flow Cytometry; Gene Expression; Humans; Irinotecan; Isoenzymes; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Uterine Cervical Neoplasms | 2014 |
Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A1*6 and UGT1A1*28 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Glucuronosyltransferase; Heterozygote; Humans; Irinotecan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Polymorphism, Genetic; Uterine Cervical Neoplasms | 2013 |
A novel diagnostic criterion for lymph node metastasis in cervical cancer using multi-detector computed tomography.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Female; Humans; Hysterectomy; Irinotecan; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Multidetector Computed Tomography; Neoadjuvant Therapy; Organoplatinum Compounds; Precision Medicine; Uterine Cervical Neoplasms | 2013 |
Analysis of prognostic factors for patients with bulky squamous cell carcinoma of the uterine cervix who underwent neoadjuvant chemotherapy followed by radical hysterectomy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Hysterectomy; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Risk Factors; Survival Rate; Tomography, X-Ray Computed; Tumor Burden; Uterine Cervical Neoplasms | 2015 |
PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
Topics: Activation, Metabolic; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Child; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Humans; Irinotecan; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Proteins; Polo-Like Kinase 1; Prodrugs; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proteolysis; Proto-Oncogene Proteins; Pteridines; Rhabdomyosarcoma, Embryonal; Sarcoma, Ewing; Skin Neoplasms; Topoisomerase I Inhibitors; Ubiquitination; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Has-miR-30a regulates autophagic activity in cervical cancer upon hydroxycamptothecin exposure.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Binding Sites; Camptothecin; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Membrane Proteins; MicroRNAs; RNA Interference; Signal Transduction; Time Factors; Transfection; Uterine Cervical Neoplasms | 2015 |
A study of the synergistic effect of folate-decorated polymeric micelles incorporating Hydroxycamptothecin with radiotherapy on xenografted human cervical carcinoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Chemoradiotherapy; Drug Delivery Systems; Female; Fluorodeoxyglucose F18; Folic Acid; G2 Phase Cell Cycle Checkpoints; HeLa Cells; Histones; Humans; Mice, Inbred BALB C; Mice, Nude; Micelles; Microscopy, Electron, Transmission; Phosphorylation; Polyesters; Polyethylene Glycols; Polymers; Positron-Emission Tomography; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Gamma Rays; Humans; Hysterectomy; Injections, Intravenous; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Survival Analysis; Thrombocytopenia; Treatment Outcome; Uterine Cervical Neoplasms | 2016 |
Cancer Targeted Enzymatic Theranostic Prodrug: Precise Diagnosis and Chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Transformation, Neoplastic; Female; Humans; Irinotecan; Lung Neoplasms; Mice; NAD(P)H Dehydrogenase (Quinone); Prodrugs; Uterine Cervical Neoplasms | 2016 |
Hydroxycamptothecin shows antitumor efficacy on HeLa cells via autophagy activation mediated apoptosis in cervical cancer.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; bcl-2-Associated X Protein; Beclin-1; Blotting, Western; Camptothecin; Caspase 3; Cell Survival; Drug Screening Assays, Antitumor; Female; HeLa Cells; Humans; Membrane Proteins; Microtubule-Associated Proteins; Proto-Oncogene Proteins c-bcl-2; RNA-Binding Proteins; Uterine Cervical Neoplasms | 2016 |
A green approach to dual-drug nanoformulations with targeting and synergistic effects for cancer therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Camptothecin; Cell Survival; Chitosan; Delayed-Action Preparations; Drug Carriers; Drug Combinations; Drug Compounding; Drug Stability; Drug Synergism; Female; Green Chemistry Technology; HeLa Cells; Humans; Methotrexate; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Nanoparticles; Solubility; Technology, Pharmaceutical; Tissue Distribution; Tumor Burden; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Female; Flow Cytometry; Humans; Irinotecan; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms | 2009 |
Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Polymorphism, Genetic; Prognosis; Prospective Studies; Risk Factors; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult | 2009 |
The synthesis of a c(RGDyK) targeted SN38 prodrug with an indolequinone structure for bioreductive drug release.
Topics: Camptothecin; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Indolequinones; Integrin alphaVbeta3; KB Cells; Molecular Structure; NAD(P)H Dehydrogenase (Quinone); Oxidation-Reduction; Peptides, Cyclic; Prodrugs; Structure-Activity Relationship; Time Factors; Uterine Cervical Neoplasms | 2010 |
[Results of neoadjuvant chemotherapy using tri-weekly CDDP/CPT-11 for locally advanced cervical cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Female; Humans; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Squamous Cell; Survival Rate; Uterine Cervical Neoplasms | 2010 |
Neoadjuvant chemotherapy followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for Stage IB2-IIB cervical cancer--irinotecan and platinum chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Hysterectomy; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms | 2010 |
A modified shortened administration schedule for neoadjuvant chemotherapy with irinotecan and cisplatin in locally advanced cervical cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Time Factors; Treatment Outcome; Uterine Cervical Neoplasms | 2011 |
Clinical effects of irinotecan hydrochloride in combination with cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2011 |
Demethylation restores SN38 sensitivity in cells with acquired resistance to SN38 derived from human cervical squamous cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Azacitidine; Calcium-Calmodulin-Dependent Protein Kinases; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Dealkylation; Death-Associated Protein Kinases; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Uterine Cervical Neoplasms | 2012 |
[Study of irinotecan-induced toxicity and its correlation to UGT1A1 gene promoter polymorphisms].
Topics: Adult; Alleles; Amplified Fragment Length Polymorphism Analysis; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Diarrhea; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Middle Aged; Neutropenia; Ovarian Neoplasms; Polymorphism, Genetic; Promoter Regions, Genetic; Uterine Cervical Neoplasms | 2011 |
Fertility-sparing management for bulky cervical cancer using neoadjuvant transuterine arterial chemotherapy followed by vaginal trachelectomy.
Topics: Adult; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cervix Uteri; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Irinotecan; Lymph Node Excision; Neoadjuvant Therapy; Organoplatinum Compounds; Pregnancy; Retrospective Studies; Uterine Artery Embolization; Uterine Cervical Neoplasms; Vagina | 2012 |
Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Azacitidine; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Exodeoxyribonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; RecQ Helicases; RNA, Small Interfering; Topoisomerase I Inhibitors; Uterine Cervical Neoplasms; Werner Syndrome Helicase | 2012 |
[A case of large cell neuroendocrine carcinoma (LCNEC) of the uterine cervix successfully treated by postoperative CPT-11+CDDP chemotherapy after non-curative surgery].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Neoplasm Invasiveness; Tomography, X-Ray Computed; Uterine Cervical Neoplasms | 2012 |
Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Uterine Cervical Neoplasms | 2013 |
Concurrent radiation therapy and irinotecan in stage IIIB cervical cancer.
Topics: Adult; Camptothecin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Humans; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Radiation Dosage; Radiation-Sensitizing Agents; Radiotherapy, High-Energy; Thailand; Treatment Outcome; Uterine Cervical Neoplasms | 2003 |
Combined effect of sodium selenite and campthotecin on cervical carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma; Caspase 3; Caspases; Cell Division; Cell Line, Tumor; Cell Nucleus; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Activation; Female; HeLa Cells; Humans; Mitochondria; Oxidative Stress; Sodium Selenite; Time Factors; Uterine Cervical Neoplasms | 2004 |
[Present-day potential of medication for disseminated cervical carcinoma].
Topics: Antineoplastic Agents; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Uterine Cervical Neoplasms | 2004 |
[Chemotherapy using nedaplatin for advanced gynecologic cancers].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Adenosquamous; Combined Modality Therapy; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms | 2004 |
Combination effects of irradiation and irinotecan on cervical squamous cell carcinoma cells in vitro.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Cell Survival; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Irinotecan; Radiation Tolerance; Radiotherapy; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2005 |
[Clinical effects of combination chemotherapy with irinotecan hydrochloride and cisplatin on cervical cancer: study of 46 patients].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Hysterectomy; Irinotecan; Middle Aged; Radiotherapy, Adjuvant; Uterine Cervical Neoplasms | 2005 |
Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro.
Topics: Antigens, CD20; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; CD40 Antigens; Cell Survival; Clone Cells; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Resistance, Neoplasm; Etoposide; Female; Flow Cytometry; Fluorouracil; Humans; Integrin alpha1; Integrin alpha6; Irinotecan; Mitomycin; Uterine Cervical Neoplasms; X-Rays | 2006 |
Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Combined Modality Therapy; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin G; Immunoglobulin M; Irinotecan; Lymphocytes, Tumor-Infiltrating; Lymphotoxin beta Receptor; Mice; Mice, Inbred BALB C; Mice, Nude; Random Allocation; Recombinant Fusion Proteins; Single-Blind Method; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2006 |
[Outpatient chemotherapy in gynecologic oncology].
Topics: Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Doxorubicin; Drug Administration Schedule; Female; Humans; Irinotecan; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Uterine Cervical Neoplasms; Uterine Neoplasms | 2006 |
Inhibitory effect of HCPT on expression of HIF-1alpha and downstream genes in hypoxic human cervical SiHa cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Hypoxia; Cell Line, Tumor; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; RNA, Messenger; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A | 2007 |
[Combined irinotecan (CPT-11) and nedaplatin (254-S) therapy for advanced and/or recurrent cervical cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Female; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Recurrence; Tomography, X-Ray Computed; Uterine Cervical Neoplasms | 2008 |
Irinotecan HCl, an anticancer topoisomerase I inhibitor, frequently induces ovarian failure in premenopausal and perimenopausal women.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Ovary; Perimenopause; Premenopause; Primary Ovarian Insufficiency; Treatment Outcome; Uterine Cervical Neoplasms | 2008 |
[Evaluation of a new anti-cancer drug regimen against uterine cervical cancer in nude mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Mice; Mice, Nude; Mitomycin; Neoplasm Transplantation; Paclitaxel; Uterine Cervical Neoplasms | 1997 |
Clonal analysis of cancer cells that survived anticancer drug treatment.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Cell Survival; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Humans; Irinotecan; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 1997 |
Retroviral expression of a mutant (Gly-533) human DNA topoisomerase I cDNA confers a dominant form of camptothecin resistance.
Topics: Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; DNA Topoisomerases, Type I; DNA, Complementary; Drug Resistance, Microbial; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glycine; HeLa Cells; Humans; Mutation; Neomycin; Nucleic Acid Conformation; Polymerase Chain Reaction; Retroviridae; Transduction, Genetic; Transfection; Uterine Cervical Neoplasms | 1999 |
Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cell Survival; Combined Modality Therapy; DNA Topoisomerases, Type I; Dose-Response Relationship, Radiation; Enzyme Inhibitors; Female; Humans; Inhibitory Concentration 50; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2000 |
Irinotecan: a new agent comes of age.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Female; Gastrointestinal Neoplasms; Humans; International Cooperation; Irinotecan; Male; Ovarian Neoplasms; Uterine Cervical Neoplasms | 2001 |
Impact on survival following successful neoadjuvant chemotherapy and radical surgery for Stage IIb bulky and Stage IIIb cervical cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase II as Topic; Disease-Free Survival; Female; Humans; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Peplomycin; Uterine Cervical Neoplasms | 2001 |
[A modified administrated schedule for combination therapy with irinotecan and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical cancer--a report of 2 cases as a pilot study].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Adenosquamous; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Neoadjuvant Therapy; Pilot Projects; Uterine Cervical Neoplasms | 2001 |
Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cell Division; Cisplatin; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Neoplasm Proteins; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2001 |
Evidence of an association between human papillomavirus and impaired chemotherapy-induced apoptosis in cervical cancer cells.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Caspase 3; Caspases; Cell Survival; Cisplatin; Cytochrome c Group; Enzyme Activation; Female; Flow Cytometry; Humans; Papillomaviridae; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2002 |
Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Prodrugs; Random Allocation; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2002 |